Bacterial Vaginosis Biofilms: Challenges to Current Therapies and Emerging Solutions

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2016 Feb 3

PMID 26834706

Citations 81

Authors

Daniela Machado

Joana Castro

Ana Palmeira-de-Oliveira

Jose Martinez-de-Oliveira

Nuno Cerca

Affiliations

Soon will be listed here.

Abstract

Bacterial vaginosis (BV) is the most common genital tract infection in women during their reproductive years and it has been associated with serious health complications, such as preterm delivery and acquisition or transmission of several sexually transmitted agents. BV is characterized by a reduction of beneficial lactobacilli and a significant increase in number of anaerobic bacteria, including Gardnerella vaginalis, Atopobium vaginae, Mobiluncus spp., Bacteroides spp. and Prevotella spp.. Being polymicrobial in nature, BV etiology remains unclear. However, it is certain that BV involves the presence of a thick vaginal multi-species biofilm, where G. vaginalis is the predominant species. Similar to what happens in many other biofilm-related infections, standard antibiotics, like metronidazole, are unable to fully eradicate the vaginal biofilm, which can explain the high recurrence rates of BV. Furthermore, antibiotic therapy can also cause a negative impact on the healthy vaginal microflora. These issues sparked the interest in developing alternative therapeutic strategies. This review provides a quick synopsis of the currently approved and available antibiotics for BV treatment while presenting an overview of novel strategies that are being explored for the treatment of this disorder, with special focus on natural compounds that are able to overcome biofilm-associated antibiotic resistance.

Citing Articles

Immunoinformatic evaluation for the development of a potent multi-epitope vaccine against bacterial vaginosis caused by Gardnerella vaginalis.

Motamedi H, Shoja S, Abbasi M PLoS One. 2025; 20(2):e0316699.

PMID: 40014550 PMC: 11867334. DOI: 10.1371/journal.pone.0316699.

Mechanisms of S. agalactiae promoting G. vaginalis biofilm formation leading to recurrence of BV.

Li M, Zeng Z, Wang X, Liu Y, Wei H, Liu J NPJ Biofilms Microbiomes. 2024; 10(1):138.

PMID: 39604369 PMC: 11603151. DOI: 10.1038/s41522-024-00601-w.

Ceragenins Prevent the Development of Murine Vaginal Infection Caused by .

Wnorowska U, Piktel E, Daniluk T, Paprocka P, Savage P, Durnas B Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598357 PMC: 11597204. DOI: 10.3390/ph17111445.

Evaluation of the Vaginal Panel Realtime PCR kit (Vircell, SL) for diagnosing vaginitis: A comparative study with routinely used diagnostics.

Amor I, Alberola A, De Salazar A, Vinuela L, Ubeda-Portugues S, Galan M PLoS One. 2024; 19(11):e0313414.

PMID: 39504318 PMC: 11540222. DOI: 10.1371/journal.pone.0313414.

The cAMP receptor protein from Gardnerella vaginalis is not regulated by ligands.

Dong H, Zhang J, Zhang K, Zhang F, Wang S, Wang Q Commun Biol. 2024; 7(1):1233.

PMID: 39354127 PMC: 11445507. DOI: 10.1038/s42003-024-06957-1.

References

Rothman K, Funch D, Alfredson T, Brady J, Dreyer N . Randomized field trial of vaginal douching, pelvic inflammatory disease and pregnancy. Epidemiology. 2003; 14(3):340-8. View

Ison C, TAYLOR R, Link C, Buckett P, Harris J, Easmon C . Local treatment for bacterial vaginosis. Br Med J (Clin Res Ed). 1987; 295(6603):886. PMC: 1247931. DOI: 10.1136/bmj.295.6603.886. View

Guerra B, Ghi T, Quarta S, Morselli-Labate A, Lazzarotto T, Pilu G . Pregnancy outcome after early detection of bacterial vaginosis. Eur J Obstet Gynecol Reprod Biol. 2006; 128(1-2):40-5. DOI: 10.1016/j.ejogrb.2005.12.024. View

Paavonen J, Mangioni C, Martin M, Wajszczuk C . Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial. Obstet Gynecol. 2000; 96(2):256-60. DOI: 10.1016/s0029-7844(00)00902-9. View

Hantoushzadeh S, Golshahi F, Javadian P, KHazardoost S, Aram S, Hashemi S . Comparative efficacy of probiotic yoghurt and clindamycin in treatment of bacterial vaginosis in pregnant women: a randomized clinical trial. J Matern Fetal Neonatal Med. 2011; 25(7):1021-4. DOI: 10.3109/14767058.2011.614654. View

Hymes S, Randis T, Sun T, Ratner A . DNase inhibits Gardnerella vaginalis biofilms in vitro and in vivo. J Infect Dis. 2013; 207(10):1491-7. PMC: 3627197. DOI: 10.1093/infdis/jit047. View

Blackwell A . Tea tree oil and anaerobic (bacterial) vaginosis. Lancet. 1991; 337(8736):300. DOI: 10.1016/0140-6736(91)90910-h. View

Holley R, Richter H, Varner R, Pair L, Schwebke J . A randomized, double-blind clinical trial of vaginal acidification versus placebo for the treatment of symptomatic bacterial vaginosis. Sex Transm Dis. 2004; 31(4):236-8. DOI: 10.1097/01.olq.0000118423.20985.e7. View

Algburi A, Volski A, Chikindas M . Natural antimicrobials subtilosin and lauramide arginine ethyl ester synergize with conventional antibiotics clindamycin and metronidazole against biofilms of Gardnerella vaginalis but not against biofilms of healthy vaginal lactobacilli. Pathog Dis. 2015; 73(5). DOI: 10.1093/femspd/ftv018. View

10.

Tally F, Sutter V, Finegold S . Treatment of anaerobic infections with metronidazole. Antimicrob Agents Chemother. 1975; 7(5):672-5. PMC: 429201. DOI: 10.1128/AAC.7.5.672. View

11.

Boskey E, Telsch K, Whaley K, Moench T, Cone R . Acid production by vaginal flora in vitro is consistent with the rate and extent of vaginal acidification. Infect Immun. 1999; 67(10):5170-5. PMC: 96867. DOI: 10.1128/IAI.67.10.5170-5175.1999. View

12.

Donders G, Guaschino S, Peters K, Tacchi R, Lauro V . A multicenter, double-blind, randomized, placebo-controlled study of rifaximin for the treatment of bacterial vaginosis. Int J Gynaecol Obstet. 2013; 120(2):131-6. DOI: 10.1016/j.ijgo.2012.08.022. View

13.

Xu S, Cavera V, Rogers M, Huang Q, Zubovskiy K, Chikindas M . Benzoyl peroxide formulated polycarbophil/carbopol 934P hydrogel with selective antimicrobial activity, potentially beneficial for treatment and prevention of bacterial vaginosis. Infect Dis Obstet Gynecol. 2014; 2013:909354. PMC: 3870611. DOI: 10.1155/2013/909354. View

14.

Togni G, Battini V, Bulgheroni A, Mailland F, Caserini M, Mendling W . In vitro activity of nifuratel on vaginal bacteria: could it be a good candidate for the treatment of bacterial vaginosis?. Antimicrob Agents Chemother. 2011; 55(5):2490-2. PMC: 3088278. DOI: 10.1128/AAC.01623-10. View

15.

Valeria Bahamondes M, Portugal P, Brolazo E, Simoes J, Bahamondes L . Use of a lactic acid plus lactoserum intimate liquid soap for external hygiene in the prevention of bacterial vaginosis recurrence after metronidazole oral treatment. Rev Assoc Med Bras (1992). 2011; 57(4):415-20. DOI: 10.1590/s0104-42302011000400015. View

16.

Bradshaw C, Morton A, Hocking J, Garland S, Morris M, Moss L . High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006; 193(11):1478-86. DOI: 10.1086/503780. View

17.

Dickey L, Nailor M, Sobel J . Guidelines for the treatment of bacterial vaginosis: focus on tinidazole. Ther Clin Risk Manag. 2009; 5(3):485-9. PMC: 2710380. DOI: 10.2147/tcrm.s3777. View

18.

Chavoustie S, Jacobs M, Reisman H, Waldbaum A, Levy S, Hillier S . Metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis: a dose-ranging study. J Low Genit Tract Dis. 2014; 19(2):129-34. PMC: 4376277. DOI: 10.1097/LGT.0000000000000062. View

19.

McMillan A, Dell M, Zellar M, Cribby S, Martz S, Hong E . Disruption of urogenital biofilms by lactobacilli. Colloids Surf B Biointerfaces. 2011; 86(1):58-64. DOI: 10.1016/j.colsurfb.2011.03.016. View

20.

Hooven T, Randis T, Hymes S, Rampersaud R, Ratner A . Retrocyclin inhibits Gardnerella vaginalis biofilm formation and toxin activity. J Antimicrob Chemother. 2012; 67(12):2870-2. PMC: 3494843. DOI: 10.1093/jac/dks305. View